Clinical Assessment of Postoperative Immunochemotherapy for Non-Small Cell Lung Cancer.
スポンサーリンク
概要
- 論文の詳細を見る
A study of postoperative adjuvant chemotherapy according to cell type and curability, either combined with or without immunotherapy using OK-432 was carried out in 138 patients with lung cancer who underwent resective surgery. Administration of OK-432 was selected by randomization.<BR>Of the total number of lung cancer cases, 123 patients were evaluable.<BR>Five-year survival rates were 66.3% in OK-432 group (A), and 51.0% in control group (B), with no significant differences between the two groups. However, in patients who were curatively resected, the 5-year survival rate of the OK-432 group were significantly better than that of the control group (group A; 70.9%, group B; 50.8%, p<0.05), in particular in the adenocarcinoma group and Stage I group (p<0.05).<BR>Therefore, the postoperative administration of OK-432 with chemotherapy contributed to improve the survival rate of curatively operated patients with lung cancer.
- 特定非営利活動法人 日本肺癌学会の論文
特定非営利活動法人 日本肺癌学会 | 論文
- 診療科からみた新しいTNM病期分類（UICC-7）の問題点と課題?画像診断からみた問題点と課題?
- 新潟県における肺がんの解析
- 慢性血栓塞栓性肺高血圧症合併肺腺癌に対する左上葉切除術を施行した1例
- 肺がん検診における判定基準の改訂（2）：B，C，D判定に関して
- 片側性多発脳神経障害（Garcin症候群）を契機に発見され，化学療法により神経症状の改善を得た小細胞肺癌の1例